Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Rhea-AI Summary
Vericel (NASDAQ:VCEL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company’s Investor Relations website at http://investors.vcel.com.
Positive
- None.
Negative
- None.
News Market Reaction – VCEL
In the Jan 6 session, VCEL gained 6.09%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Conference presentation | Neutral | +0.1% | Announcement of participation in Stephens Annual Investment Conference via webcast. |
| Nov 06 | Earnings results | Positive | +4.2% | Record Q3 2025 revenue, margin strength, and reaffirmed full‑year guidance. |
| Oct 23 | Earnings date notice | Neutral | -1.2% | Scheduling of Q3 2025 earnings call and webcast details for investors. |
| Aug 28 | Conference appearance | Neutral | +0.0% | Notice of participation in Wells Fargo Healthcare Conference fireside chat. |
| Jul 31 | Earnings results | Positive | -14.1% | Strong Q2 2025 revenue, margin expansion, and MACI growth but sharp selloff. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases showed one positive and one sharply negative reaction, while conference announcements typically had minimal price impact.
Over the last six months, Vericel reported strong quarterly results on Jul 31, 2025 and Nov 6, 2025, with growing revenue, higher gross margins, and reaffirmed guidance. Market reactions to these earnings were mixed, including a -14.07% move despite positive Q2 metrics and a +4.17% move on Q3 results. Multiple conference and presentation notices, such as on Aug 28, 2025 and Nov 14, 2025, saw near-flat price changes, indicating that routine investor‑relations events have historically had limited immediate impact.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2026 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
